Navigation Links
HspE7 in Medical News

Nventa presents HspE7 data at international HPV conference

Preclinical Data Indicate New HspE7 Promotes More Potent Immune Responses SAN DIEGO, CA, Nov. 5 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation (TSX:NVN) today presented additional preclinical data on new HspE7 at the 24th International Papillomavirus conference, the largest annu...
HspE7 in Medical Technology

Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial

All Patients in Cohort 3 Demonstrated Improvement in T-Cell Responses Further Supporting the Therapeutic Potential of HspE7 SAN DIEGO, May 12 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced positive immunological data from the third cohort of...

Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial

- HspE7 Phase 2 Trial for Cervical Dysplasia to Begin Mid-2008 - SAN DIEGO, April 24 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced the completion of the safety and tolerability assessment of the fourth and final cohort of patients in its Phase 1...

Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial

3 out of 4 Patients in Cohort 2 Demonstrate T-Cell Responses Indicating Potential HspE7 Therapeutic Benefit SAN DIEGO, March 26 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced interim immunological data from the first two cohorts of i...

Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial

SAN DIEGO, March 11 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced that the Company has completed enrollment and initiated dosing of the fourth and final cohort of patients in its Phase 1 dose escalation trial. This study examines the safety of its l...

Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial

- HspE7 Well Tolerated; Fourth Cohort to be Dosed Shortly - SAN DIEGO, March 3 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced the completion of the safety and tolerability assessment of its third cohort of patients in a Phase 1 clinical trial o...

Nventa Announces Presentation of Positive HspE7 Data from NCI-Sponsored Clinical Trial in Cervical Dysplasia

- 78 Percent of Patients Showed Complete Response or Reduction of Lesion Size by More than Fifty Percent - SAN DIEGO, CA, March 05, 2007 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation today announced the presentation of positive results from a clinical trial examining the safety an...

Initiation of Coverage Informational Review Issued by Scimitar Equity Research

...tp://www.nventacorp.com . About HspE7, Nventa's Lead Product Candidate: hspe7 is a novel therapeutic vaccine candidate for the treatment of diseases caus...s (HPV), one of the most common sexually transmitted diseases in the world. hspe7 is derived from Nventa's proprietary CoVal(TM) fusion platform, which uses ...
HspE7 in Biological Technology

Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial

SAN DIEGO, CA, Dec. 6 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced that the Company has completed enrollment and initiated dosing of the second cohort of patients in its Phase 1 dose escalation trial examining the safety of its lead candidate, HspE7...

Nventa announces publication of HspE7 data

- HspE7 Demonstrates Ability to Elicit Long-Lasting Tumor Protection In Vivo; Lead Candidate May Have Utility in HPV-infected Patients With Invasive Cancer and/or HIV - SAN DIEGO, CA, Sept. 24 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation (TSX:NVN) today ...

Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial

- Conference Call on September 13 to Discuss Phase 1 Trial and Other Major Milestones - SAN DIEGO, CA, Sept. 10 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation (TSX:NVN) today announced the initiation of its Phase 1 clinical trial to assess the safety...

Nventa updates progress of cervical dysplasia trial with new HspE7

-- Company Completes Enrollment in First Cohort -- SAN DIEGO, CA, Oct. 18 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation (TSX:NVN) today announced that the Company has completed enrollment of the first cohort in its Phase 1 clinical trial to assess the safety and tol...

Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights

...e fourth cohort were administered 500 mcg of hspe7 and 2,000 mcg of Poly-ICLC. These data support doses of 500 mcg of hspe7 and 1,000-2,000 mcg of Poly ICLC as appropri...nformation concerning: the immunologic activity of hspe7 in treating CIN; that we identified an optimal dos...

Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR

...nclude Phase 2 clinical studies that will evaluate hspe7 as a potential treatment for both low-grade cervic... do, that such studies will not support the use of hspe7 as a treatment for CIN 1 or CIN 2/3; that we will ...nned and that such studies will support the use of hspe7 as a treatment for CIN 1 and CIN 2/3; that we will...

Nventa Appoints Gordon H. Busenbark to Board of Directors

...at Burroughs Corporation. He received a bachelor of science degree in accounting and an MBA from the University of Utah in Salt Lake City. "Nventa's hspe7 therapeutic vaccine for the treatment of HPV-related diseases places the company at the center of a very exciting segment of the drug development indu...

Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results

... - Company Advancing Lead Candidate hspe7 into Phase 2 Clinical Trial in ...sia clinical trial examining the safety of new hspe7 leading to the recent completion of enrollment...conference demonstrating that co-administering hspe7 with certain adjuvants promotes more potent re...

Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results

...the first cohort of patients in the Company's hspe7 Phase 1 clinical trial in cervical intraepithelial...ce and Clinical Workshop that demonstrate that new hspe7 promotes more potent immune responses; - G...ccine Immunology demonstrating ability of new hspe7 to elicit long-lasting tumor protection in vivo, ...
Other Tags
(Date:5/6/2015)... 2015 Wolters Kluwer , a ... students, announced today that in a survey of nearly ... of the clinical decision support resource improves the quality ... 2014, UpToDate users in more than 170 countries worldwide ... on average. In Germany alone, 95% of all university ...
(Date:5/6/2015)... 06, 2015 Healthcare jobs ... after launching in mid-February. The company connects hospitals, home-health, ... previous experience in the industry. Likewise, job seekers are ... to Kyle Johnson, CTO, unique traffic to the site ... month: "Each new job posting brings targeted, interested candidates ...
(Date:5/6/2015)... Locally owned, Greek olive oil producer and importer, Our Family’s ... one the best Extra Virgin Olive Oils in the world. ... Greece and known as Laconiko , received the ... Oil, which is defined by the competition as “the perfect ... applicants from 25 different countries applying, Laconiko stood out as ...
(Date:5/6/2015)... 06, 2015 Dr. Vito C. Quatela, one ... , recently completed a medical mission trip to Hanoi, Vietnam ... those affected by microtia and other deformities of the face. ... and ended on April 26, Dr. Quatela and his team ... a congenital deformity where the outside of the ear is ...
(Date:5/6/2015)... Los Angeles, California (PRWEB) May 06, 2015 ... has secured its first round of VC funding and ... , The enterprise class embeddable software enables applications ... transform data as it moves between systems and locations. ... the HyperTransfer technology moves files at line speed, independent ...
Breaking Medicine News(10 mins):Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 2Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 3Health News:Job Seekers Turn to JobMedic to Find Healthcare Positions - JobMedic.com Reaches 1,000 User Milestone 2Health News:Greek Extra Virgin Olive Oil, Laconiko Wins Gold at the NYIOOC and Is Featured in Olive Oil Times as One of Greece's Best EVOO's for 2015 2Health News:Dr. Vito Quatela Completes Successful 10-Day Medical Mission Trip to Hanoi, Vietnam 2Health News:Dr. Vito Quatela Completes Successful 10-Day Medical Mission Trip to Hanoi, Vietnam 3Health News:TransferSoft Launches Industry’s Most Comprehensive Data Movement Technology Suite to Optimize Disaster Recovery, Big Data, and Cloud Applications 2Health News:TransferSoft Launches Industry’s Most Comprehensive Data Movement Technology Suite to Optimize Disaster Recovery, Big Data, and Cloud Applications 3Health News:TransferSoft Launches Industry’s Most Comprehensive Data Movement Technology Suite to Optimize Disaster Recovery, Big Data, and Cloud Applications 4
(Date:3/31/2015)... 31, 2015  Elephant Talk Communications Corp. (NYSE MKT: ... of Software Defined Network Architecture (ET Software DNA® 2.0) ... of approximately $20.4 million for the year ended December ... for the year ended December 31, 2013. ... had completed its multi-year transition away from its legacy ...
(Date:3/24/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has ... Global Strategic Business Report" report to their offering. ... in US$ Thousands by the following Segments: Face Biometrics, and Voice ... Canada , Japan , ... East & Africa , and ...
(Date:3/23/2015)... 23, 2015  In the 2014 fiscal year, irs.gov ... losses. This figure accounts for a fraction of the ... Nilson Report, exceeds $11 billion globally. The polygraph has ... crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test in ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
Other Contents